Searle chairman Sheldon Gilgore said Searle's operating  loss in 1987 will be less than the 87 mln dlr operating loss in  1986.
Gilgore said the company intends to have sales of three  billion dlrs by the mid-1990s.
He said the company anticipates approval in Japan, the  U.S., Italy, Spain and the U.K. for its ulcer treatment drug  Cytotech.
He also said that in a paper not yet published the drug was  shown to prevent a flare-up of ulcers for a longer period of  time than Tagamet, made by SmithKline Beckman Corp &lt;SKB>.